What should teams do when they cannot find a vendor with AI and LLM security built for healthcare use cases?

Teams should not settle for generic testing claims without evidence. They should define the controls they need, require security testing that addresses AI specific weaknesses, and evaluate whether the provider can support sensitive data handling, regulatory alignment, and remediation workflows. If the market gap remains, organisations may need a mixed approach that combines internal governance with specialised external assessment.

When the healthcare AI security vendor market is too thin to trust

Healthcare teams should treat a shortage of fit-for-purpose vendors as a governance problem, not a buying inconvenience. If a provider cannot show testing depth for AI-specific failure modes, handling of protected data, or a credible remediation path, the gap is in the control environment, not just the procurement shortlist. The strongest external references here are NIST AI Risk Management Framework and the OWASP Top 10 for Agentic Applications 2026, because they help teams define what adequate assurance should cover even when no vendor package is tailored to healthcare.

What practitioners often miss is that “healthcare-ready” is not a binary product label. It is a combination of data sensitivity, workflow criticality, clinical context, and the ability to evidence controls under scrutiny. In practice, many security teams encounter the real limit only after procurement has already narrowed the field to vendors whose testing claims do not survive clinical, privacy, or audit review.

How to build an assurance model when the market has no obvious fit

The practical response is to split the problem into control requirements, evidence requirements, and operating model. First, define the AI and LLM security outcomes you need: prompt-injection resistance, data segregation, logging, human review points, model change control, and clear remediation ownership. Then ask vendors to demonstrate those outcomes with artifacts, not slogans. A generic “we test our AI” statement is not useful unless it is tied to specific failure classes, coverage boundaries, and retest triggers.

For healthcare use cases, the question is also whether the vendor can support the surrounding control environment. That includes sensitive data handling, role-based access to outputs, auditability for patient-impacting decisions, and integration into privacy and incident response workflows. If the vendor cannot evidence those elements, the team should not assume compensating policies will fill the gap later.

Use a control matrix that separates AI application risk from data governance, clinical workflow risk, and supplier assurance.
Require test evidence that names the threat classes covered and the boundaries of the testing.
Verify who owns remediation, retesting, exception handling, and rollback when a defect affects a live workflow.
Keep a fallback path for independent assessment when the supplier cannot provide sufficiently specific evidence.

The most effective mixed model is often internal governance plus targeted external review, especially when the vendor market is immature. That approach preserves accountability while avoiding overreliance on a supplier’s self-attestation. The guidance breaks down when an organisation treats a one-time evaluation as enough and fails to revisit controls after model updates, workflow changes, or new data uses.

Where the edge cases and trade-offs show up

Tighter assurance often increases procurement friction and integration overhead, so teams have to balance speed against evidentiary confidence. That trade-off becomes sharper in healthcare because a tool that is acceptable for low-risk administrative use may be unsuitable for anything that touches clinical advice, patient data, or regulated records.

One edge case is when the vendor is strong on model capability but weak on healthcare governance. Another is when the vendor offers broad security claims but cannot map them to the organisation’s actual use case. In both cases, the safer answer is not to widen the scope until the claims fit, but to narrow the use case until the controls are defensible. If the use case still cannot be covered, the team should treat that as a sign to defer deployment rather than to accept vague assurance.

There is also a genuine consensus gap in the market about what “AI security testing” should include for LLM-based workflows. Until that matures, teams should prefer evidence that is specific, repeatable, and tied to the actual workflow over general statements about responsible AI. When healthcare data or decision support is involved, weak evidence is not a temporary inconvenience; it is a sign that the control assumption is not yet trustworthy.

Risk and Threat Considerations

The main risk is false assurance. In healthcare, that can expose sensitive data, weaken trust in model-assisted workflows, or leave organisations unable to demonstrate that they assessed AI-specific failure modes before deployment. The absence of a suitable vendor often means the organisation is operating in a higher-risk market condition, not a lower-risk one.

Failure mechanism: Security gaps emerge when teams rely on generic AI claims that do not test prompt injection, unsafe output handling, data leakage, or workflow abuse under healthcare conditions. A supplier may appear capable at the product level while still lacking the evidence needed to show safe operation in a regulated environment.

Impact: The result can be unverified exposure of patient information, weak auditability, delayed remediation, and control decisions that cannot stand up to governance review. In the worst case, the organisation adopts a tool that is operationally useful but not defensible for healthcare use.

Standards & Framework Alignment

This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.

OWASP Agentic AI Top 10 address the attack and risk surface, while NIST AI RMF, NIST AI 600-1 and CIS Controls v8 set the governance and control requirements practitioners need to meet.

Framework	Control / Reference	Relevance
NIST AI RMF	GV-1 — Govern	Sets AI risk governance expectations when vendors cannot evidence healthcare-fit assurance.
Recommendation — Define AI risk controls and approval criteria before accepting any vendor claim.
NIST AI 600-1	MAP-1 — Map the AI Context	Helps teams scope healthcare use cases, data sensitivity, and workflow context.
	MEASURE-2 — Measure and Analyze Risks	Supports evidence-based evaluation of AI-specific weaknesses and testing coverage.
Recommendation — Map the clinical context and data sensitivity before selecting or accepting a tool. Require measurable evidence for the exact AI failure modes in scope.
OWASP Agentic AI Top 10	A1 — Prompt Injection	Relevant where LLM workflows may be manipulated through malicious inputs or tool prompts.
	A2 — Sensitive Data Exposure	Applies to handling healthcare data in AI outputs, logs, and tool interactions.
Recommendation — Test the workflow for prompt injection and unsafe instruction following. Verify that sensitive data is bounded in prompts, outputs, and logs.
CIS Controls v8	6 — Access Control Management	Supports role-based access and least-privilege handling for AI systems and outputs.
	17 — Incident Response Management	Relevant for remediation, rollback, and escalation when AI defects affect live workflows.
Recommendation — Enforce least-privilege access to AI systems, data, and output workflows. Tie AI defects to a defined incident response and rollback process.

Practitioner Guidance

What to prioritise: Build the decision around the exact healthcare workflow, not around the vendor category. Teams should separate low-risk administrative uses from any workflow that touches patient data, clinical decision support, or regulated records, because the assurance bar is different in each case.

What to verify: Ask for evidence that the supplier can test and retest the specific AI failure modes that matter to your use case, and confirm that remediation ownership is explicit. If the provider cannot explain how defects are found, tracked, corrected, and revalidated, the assurance model is incomplete.

Decision rule: If the vendor cannot produce defensible evidence for the controls you need, treat the gap as a signal to reduce scope, add independent assessment, or defer deployment. Do not convert weak evidence into acceptable evidence by adding policy language around it.

Practitioner takeaway: When the market lacks a healthcare-fit vendor, the right move is usually to tighten the control requirement, not to relax the standard; procurement should follow assurance, not replace it.